IRIS
Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 843
NA - Nord America 305
EU - Europa 85
AF - Africa 7
SA - Sud America 5
OC - Oceania 2
Totale 1.247
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 514
CN - Cina 313
US - Stati Uniti d'America 296
IT - Italia 20
DE - Germania 13
GB - Regno Unito 13
CZ - Repubblica Ceca 12
CA - Canada 9
FI - Finlandia 6
ZA - Sudafrica 6
LT - Lituania 5
GR - Grecia 4
BE - Belgio 3
IN - India 3
TH - Thailandia 3
AR - Argentina 2
ES - Italia 2
HK - Hong Kong 2
KG - Kirghizistan 2
SE - Svezia 2
AU - Australia 1
BD - Bangladesh 1
BR - Brasile 1
DK - Danimarca 1
EC - Ecuador 1
IE - Irlanda 1
JO - Giordania 1
KR - Corea 1
MD - Moldavia 1
MM - Myanmar 1
MY - Malesia 1
NG - Nigeria 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PE - Perù 1
PL - Polonia 1
VN - Vietnam 1
Totale 1.247
Salva come PNG Salva come JPEG
Città #
Singapore 387
Shanghai 307
Santa Clara 49
Seattle 29
Boardman 26
Munich 9
Brno 7
Helsinki 6
London 6
Johannesburg 5
Olomouc 5
Athens 4
Hangzhou 4
Milan 4
Toronto 4
Turin 4
Wilmington 4
Ashburn 3
Bangkok 3
Brussels 3
Snodland 3
Ahmedabad 2
Ann Arbor 2
Bishkek 2
Cipolletti 2
Edgerton 2
Fairfield 2
Gonars 2
Hong Kong 2
Los Angeles 2
Markham 2
Naples 2
Ottawa 2
Pamplona 2
Rome 2
San Mateo 2
Amman 1
Auckland 1
Benin City 1
Buffalo 1
Chisinau 1
Dublin 1
Duncan 1
Engelhard 1
Frankfurt am Main 1
Guayaquil 1
Hamm 1
Ho Chi Minh City 1
Kensington 1
Lawrence 1
Leawood 1
Lima 1
Manchester 1
Miami 1
New York 1
Nuremberg 1
Pretoria 1
Princeton 1
Qingdao 1
Seodaemun-gu 1
Stockholm 1
São Paulo 1
Totale 928
Salva come PNG Salva come JPEG
Nome #
Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer 41
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 31
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience 25
Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies 24
Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience 19
Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers 19
A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy 18
Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery 18
Do you agree with populations that have been defined as 'noncandidates' to receiving platinum? 17
Celecoxib plus cartioplatin in heavily pre-treated patients with recurrent ovarian carcinoma: Preliminary results of a Phase II study 17
Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy" 17
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL) 15
Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer 15
When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer 14
Advanced vulvar carcinoma: Is it worth operating? A perioperative management protocol for radical and reconstructive surgery 13
Nomogram-based prediction of cervical dysplasia persistence/recurrence 12
Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor 12
Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. 12
A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses 11
Bulky mesonephric adenocarcinoma of the uterine cervix treated with neoadjuvant chemotherapy and radical surgery: report of the first case 11
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study 10
TERAPIA PRIMARIA DEL CARCINOMA DELL'ENDOMETRIO: CHEMIOTERAPIA 10
Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses 10
Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis 9
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance 9
Management of stage III and IVa uterine cancer 9
Advances in laparoscopic surgery for cervical cancer 9
Peritoneal cytology as prognostic factor in cervical cancer 9
3D vision improves outcomes in early cervical cancer treated with laparoscopic type B radical hysterectomy and pelvic lymphadenectomy 9
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) 9
A critical assessment on the role of sentinel node mapping in endometrial cancer 9
Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach 8
Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: Association with pathological response to treatment and clinical outcome 8
Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future 8
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] 8
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms 8
Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma A Retrospective Cohort Study 7
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 7
Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 7
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment 7
Tumori dell'ovaio 7
"Tumori della vulva e della vagina" 7
Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM) 7
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO 7
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study 7
Adoptive immunotherapy with cytokine-induced killer cells generated with a new GMP-grade protocol 7
ONCOMOVIES: CANCER IN CINEMA 7
Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial 6
Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study 6
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study 6
Gemcitabine (GEM) and liposomal doxorubicin (PLO) in recurrent/metastatic breast carcinoma: A phase II study 6
Phase II Trial on Cisplatin-Adriamycin-Paclitaxel Combination as Neoadjuvant Chemotherapy for Locally Advanced Cervical Adenocarcinoma 6
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety 6
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib 6
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma 6
Clear cell carcinoma of the endometrium 6
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 6
Prospective validation of a predictive score for complete tumor resection in recurrent ovarian cancer (ROC): an intergroup study of AGO kommission OVAR, AGO-OVAR, AGO Austria, MITO and NOGGO 6
Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer 6
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) 6
Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives 6
Chemotherapy in endometrial cancer. 6
High-Risk Borderline Ovarian Tumors: Analysis of Clinicopathological Features and Prognostic Impact of Different Follow-Up Strategies 6
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 6
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol 6
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 6
Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence 6
Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives 5
Invasive Paget Disease of the Vulva. 5
Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? 5
Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV) 5
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis 5
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival 5
Tailoring adjuvant treatment in patients with uterine cancer 5
Fertility sparing surgery in early stage epithelial ovarian cancer 5
CASE CONTROL STUDY ON TWO DIFFERENT CHEMOTHERAPY REGIMENS IN ADVANCED MIXED MULLERIAN TUMOURS 5
Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review 5
Long-term safety of fertility sparing surgery in early stage ovarian cancer: Comparison to standard radical surgical procedures 5
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives 5
Il carcinoma dell'ovaio 5
Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer 5
Tumori dell'apparato genitale femminile 5
Sentinel Node Mapping Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging in Endometrial Cancer Staging 5
Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study 5
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 5
The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment 5
Reply to P.-H. Luo et al 5
Investigating the Role of Minimally Invasive Radical Hysterectomy in Cervical Cancer 5
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 5
Trophoblastic Disease Review for Diagnosis and Management A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup 5
Phase II Study of NGR-hTNF Plus Doxorubicin in Relapsed Ovarian Cancer (OC) 5
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study 5
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial 5
Pneumoperitoneum pressures during pelvic laparoscopic surgery: a systematic review and meta-analysis 5
Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors A MITO-9 Retrospective Study 5
Laparoscopic Sentinel Node Mapping in Endometrial Cancer After Hysteroscopic Injection of Indocyanine Green 5
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer 5
Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: A single center evaluation over 200 cases 5
Safety and effectiveness of Human Papillomavirus (HPV) vaccination: NCI of Milan position statement 5
Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery 5
Totale 865
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 4 3 2 3 0 0 1
2021/20228 1 0 0 1 0 0 0 1 1 2 2 0
2022/20235 2 0 1 0 0 0 0 0 1 1 0 0
2023/2024858 1 0 1 0 0 0 0 0 271 18 180 387
2024/2025667 80 108 147 42 17 273 0 0 0 0 0 0
Totale 1.551